PALISADE BIO, INC. — Director's Dealing 2026

Feb 13, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PALISADE BIO, INC. (PALI)
CIK: 0001357459
Period of Report: 2026-02-11

Reporting Person: Jones Mitchell Lawrence (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-11	Common Stock	M	8000	—	Acquired	15252	Direct
2026-02-12	Common Stock	S	1989	$1.75	Disposed	13263	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-11	Restricted Stock Units	$	M	8000	Disposed		Common Stock (8000)	Direct

Footnotes

F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 11, 2025.

F2: Includes 3,400 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025.

F3: The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5: The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.